26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JMA-IIA00324 | 29/06/2017 | 23/01/2018 | A Phase 3 Study of KW-0761 (Mogamulizumab) in Subjects with HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) | HTLV-1 associated Myelopathy (HAM) | Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. | Kyowa Kirin Co., Ltd | NULL | Completed | >=20 YEARS | No Limit | BOTH | 52 | Phase 3 | Japan |
| 2 | JPRN-JapicCTI-173608 | 15/6/2017 | 06/06/2017 | A Phase 3 Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) | HTLV-1 associated Myelopathy (HAM) | Intervention name : KW-0761 INN of the intervention : Mogamulizumab Dosage And administration of the intervention : 0.3 mg/kg, IV Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kyowa Kirin Co., Ltd. | NULL | complete | 20 | BOTH | 52 | Phase 3 | Japan | |
| 3 | NCT03191526 (ClinicalTrials.gov) | May 22, 2017 | 13/6/2017 | A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) | HTLV-1 Associated Myelopathy | Drug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline) | Kyowa Kirin Co., Ltd. | NULL | Terminated | 20 Years | N/A | All | 66 | Phase 3 | Japan |